174
Participants
Start Date
June 14, 2021
Primary Completion Date
May 31, 2029
Study Completion Date
May 31, 2029
PRL-02 injection
abiraterone decanoate for intramuscular injection
prednisone
Oral dose
dexamethasone
Oral dose
enzalutamide
Oral capsule
RECRUITING
MidLantic Urology, Bala-Cynwyd
RECRUITING
Chesapeake Urology, Towson
RECRUITING
University of Virginia Cancer Center, Charlottesville
RECRUITING
Duke Cancer Center, Durham
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Florida Urology Partners, Tampa
RECRUITING
Urology Associates PC, Nashville
WITHDRAWN
Toledo Clinical Cancer Center, Toledo
WITHDRAWN
Helios Clinical Research, LLC, Middleburg Heights
RECRUITING
Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
RECRUITING
First Urology, Jeffersonville
RECRUITING
Wichita Urology Group, Wichita
COMPLETED
XCancer Center Omaha/Urology Cancer Center, Omaha
RECRUITING
Urology Clinics of North Texas, Dallas
RECRUITING
Houston Metro Urology, Houston
RECRUITING
Oncology Consultants, Houston
WITHDRAWN
Urology San Antonio, San Antonio
RECRUITING
Arizona Urology Specialists, Tucson
RECRUITING
New Mexico Oncology Hematology Consultants Ltd, Albuquerque
RECRUITING
Los Angeles Cancer Network, Anaheim
RECRUITING
Providence Medical Group Oncology Santa Rosa, Santa Rosa
RECRUITING
Northwest Medical Specialties, Tacoma
RECRUITING
Garden Sate Urology, Morristown
RECRUITING
Pan American Center for Oncology Trials, LLC, San Juan
Astellas Pharma Global Development, Inc.
INDUSTRY